What have animal models taught us about the p53 pathway?
暂无分享,去创建一个
[1] G. Zambetti,et al. p53 Tumor‐Suppressor Genes , 2005 .
[2] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[3] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[4] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[5] T. Jacks,et al. Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389 , 2004, Molecular and Cellular Biology.
[6] T. Jacks,et al. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice , 2004, Oncogene.
[7] T. Jacks,et al. Defective apoptosis and B‐cell lymphomas in mice with p53 point mutation at Ser 23 , 2004, The EMBO journal.
[8] Kristian Helin,et al. Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.
[9] F. Alt,et al. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. , 2004, Cancer cell.
[10] U. Moll,et al. p63 and p73: roles in development and tumor formation. , 2004, Molecular cancer research : MCR.
[11] S. Lowe,et al. Suppression of tumorigenesis by the p53 target PUMA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[12] Patrick Dowd,et al. The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.
[13] D. Green,et al. p73 Induces Apoptosis via PUMA Transactivation and Bax Mitochondrial Translocation* , 2004, Journal of Biological Chemistry.
[14] Martin Schuler,et al. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.
[15] H. K. Sluss,et al. Phosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice , 2004, Molecular and Cellular Biology.
[16] S. Korsmeyer,et al. Cell Death Critical Control Points , 2004, Cell.
[17] D. Green,et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation , 2004, The Journal of cell biology.
[18] A. Multani,et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice , 2004, Nature Genetics.
[19] C. Branda,et al. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. , 2004, Developmental cell.
[20] S. Korsmeyer,et al. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. , 2003, Cancer research.
[21] Guillermina Lozano,et al. MDM2, an introduction. , 2003, Molecular cancer research : MCR.
[22] Rebecca A. Ihrie,et al. Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types , 2003, Current Biology.
[23] Andreas Villunger,et al. p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.
[24] J. Cleveland,et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.
[25] S. Akira,et al. Integral role of Noxa in p53-mediated apoptotic response. , 2003, Genes & development.
[26] A. Berns,et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.
[27] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[28] Guillermina Lozano,et al. Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.
[29] T. Greiner,et al. Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.
[30] Petr Pancoska,et al. p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.
[31] G. Lozano,et al. Disrupting TP53 in mouse models of human cancers , 2003, Human mutation.
[32] K. Kinzler,et al. PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] O. Issinger,et al. Disruption of the Regulatory β Subunit of Protein Kinase CK2 in Mice Leads to a Cell-Autonomous Defect and Early Embryonic Lethality , 2003, Molecular and Cellular Biology.
[34] M. Kastan,et al. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.
[35] M. E. Perry,et al. mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation , 2003, Molecular and Cellular Biology.
[36] M. Herlyn,et al. p16INK4A and familial melanoma. , 2003, Methods in molecular biology.
[37] M. Moynahan,et al. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans , 2002, Oncogene.
[38] S. Cory,et al. Apoptosomes: engines for caspase activation. , 2002, Current opinion in cell biology.
[39] Keisuke Kuida,et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome , 2002, Nature.
[40] E. Appella,et al. Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription , 2002, The EMBO journal.
[41] P. Jeggo,et al. Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner , 2002, Molecular and Cellular Biology.
[42] K. Helin,et al. Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.
[43] O. Kallioniemi,et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.
[44] W. El-Deiry,et al. BRCA1 Directs a Selective p53-Dependent Transcriptional Response towards Growth Arrest and DNA Repair Targets , 2002, Molecular and Cellular Biology.
[45] R. Ramirez-Solis,et al. mdmx is a negative regulator of p53 activity in vivo. , 2002, Cancer research.
[46] Nazneen Rahman,et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.
[47] K. Tsai,et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage , 2002, Nature.
[48] T. Jacks,et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[49] Stephen N. Jones,et al. Generation of an Mdm2 conditional allele in mice , 2002, Genesis.
[50] K. Kwan. Conditional alleles in mice: Practical considerations for tissue‐specific knockouts , 2002, Genesis.
[51] G. Lozano,et al. Conditional allele of mdm2 which encodes a p53 inhibitor , 2002, Genesis.
[52] The Polish Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .
[53] A. Berns,et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.
[54] Xin Lu,et al. ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.
[55] Charles J. Sherr,et al. The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.
[56] Jiawei Han,et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. Berns,et al. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.
[58] Valerie Reinke,et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.
[59] M. Serrano,et al. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. , 2001, Cancer research.
[60] Curtis C. Harris,et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.
[61] K. Helin,et al. Apaf-1 is a transcriptional target for E2F and p53 , 2001, Nature Cell Biology.
[62] P. Chappuis,et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. , 2001, Cancer research.
[63] T. Jacks,et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.
[64] Yolande F M Ramos,et al. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. , 2001, Cancer research.
[65] K. Vousden,et al. PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.
[66] K. Kinzler,et al. PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.
[67] M. Kapoor,et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. , 2001, Molecular cell.
[68] W. Gerald,et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.
[69] A. Wyllie,et al. More than one way to go. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[70] V. Rotter,et al. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.
[71] S. Korsmeyer,et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.
[72] A. Yang,et al. p63 and p73: p53 mimics, menaces and more , 2000, Nature Reviews Molecular Cell Biology.
[73] M. Kastan,et al. The many substrates and functions of ATM , 2000, Nature Reviews Molecular Cell Biology.
[74] C. Deng,et al. Roles of BRCA1 and its interacting proteins , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[75] T. Taniguchi,et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.
[76] M. Kapoor,et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[77] S. Lowe,et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. , 2000, Genes & development.
[78] Y Taya,et al. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.
[79] Andras Nagy,et al. Cre recombinase: The universal reagent for genome tailoring , 2000, Genesis.
[80] S. Korsmeyer,et al. Atm and Bax cooperate in ionizing radiation-induced apoptosis in the central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[81] K. Isselbacher,et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.
[82] M. Wolter,et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. , 1999, Cancer research.
[83] E. Stavridi,et al. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[84] S. Lowe,et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.
[85] M. Roussel,et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.
[86] Michael Bamshad,et al. Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome , 1999, Cell.
[87] D. H. Randle,et al. Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.
[88] Thomas Ried,et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.
[89] H. Vogel,et al. p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.
[90] S. Lowe,et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.
[91] C. Prives,et al. The p53 pathway , 1999, The Journal of pathology.
[92] T. Jacks,et al. The role of p53 in tumour suppression: lessons from mouse models , 1999, Cellular and Molecular Life Sciences CMLS.
[93] L. Donehower,et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[94] T. Ouchi,et al. The BRCA2 gene product functionally interacts with p53 and RAD51. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[95] T. Mak,et al. Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.
[96] K. Sakaguchi,et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. , 1998, Genes & development.
[97] José Luis de la Pompa,et al. Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo , 1998, Cell.
[98] J L Cleveland,et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.
[99] S. Lowe,et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. , 1998, Genes & development.
[100] F. Zindy,et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[101] A. Levine,et al. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[102] J. Morgan,et al. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. , 1998, Science.
[103] Hui Tian,et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.
[104] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[105] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[106] M. Kapoor,et al. Functional activation of p53 via phosphorylation following DNA damage by UV but not γ radiation , 1998 .
[107] T. Ouchi,et al. BRCA1 regulates p53-dependent gene expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[108] G. Lozano,et al. Mouse models dissect the role of p53 in cancer and development. , 1998, Seminars in cancer biology.
[109] M. Kapoor,et al. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[110] C. Deng,et al. Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways , 1998, Nature Genetics.
[111] Y Taya,et al. DNA damage induces phosphorylation of the amino terminus of p53. , 1997, Genes & development.
[112] Richard A. Ashmun,et al. Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.
[113] Yoichi Taya,et al. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.
[114] K. Kinzler,et al. A model for p53-induced apoptosis , 1997, Nature.
[115] T. Ludwig,et al. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. , 1997, Genes & development.
[116] P. Leder,et al. Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. , 1997, Cancer research.
[117] G. Zambetti,et al. Mdm‐2: “big brother” of p53 , 1997, Journal of cellular biochemistry.
[118] Y. Shiloh,et al. The genetic defect in ataxia-telangiectasia. , 1997, Annual review of immunology.
[119] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[120] D. Baltimore,et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. , 1996, Genes & development.
[121] A. Jochemsen,et al. MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.
[122] L. Donehower. The p53-deficient mouse: a model for basic and applied cancer studies. , 1996, Seminars in cancer biology.
[123] K. Vousden,et al. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.
[124] L. Chin,et al. Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.
[125] M. Oren,et al. Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.
[126] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.
[127] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[128] James Brugarolas,et al. Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.
[129] S. Korsmeyer,et al. Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death , 1995, Science.
[130] D. Grignon,et al. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. , 1995, Oncogene.
[131] Stephen J. Elledge,et al. Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.
[132] M. Lovett,et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.
[133] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[134] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[135] B. Vogelstein,et al. Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.
[136] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[137] John Calvin Reed,et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.
[138] S. Elledge,et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.
[139] B. Vogelstein,et al. No room at the p53 inn , 1993, Nature.
[140] A. Levine,et al. The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.
[141] A. Levine,et al. Gain of function mutations in p53 , 1993, Nature Genetics.
[142] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[143] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[144] S. Benchimol,et al. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. , 1993, The EMBO journal.
[145] M. Oren,et al. mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.
[146] B. Vogelstein,et al. Tumour suppressor genes. No room at the p53 inn. , 1993, Nature.
[147] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[148] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[149] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[150] B. Vogelstein,et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[151] W. Blattner,et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.
[152] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[153] A. Levine,et al. The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.